GlassScriptPhysician profile
Masood Ahmad
NPI 1699856559
$5,250.22
in general payments reported to CMS, 2019-2025
24 companies · $74.19 in 2025
The $74.19 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,702 · 2020: $1,252 · 2021: $903 · 2022: $1,307 · 2023: $13.14 · 2025: $74.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,714.41 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $868.11 | 2019-2022 | |
| Genzyme Corporation | $547.80 | 2019-2022 | |
| Amgen INC. | $442.96 | 2019-2022 | |
| Glaxosmithkline, LLC. | $428.29 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.33 | 2020-2022 | |
| Kaleo, INC. | $135.76 | 2019-2022 | |
| Covis Pharma Gmbh | $121.21 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $111.48 | 2019-2021 | |
| Tosoh Bioscience, INC. | $95.00 | 2019 | |
| Grifols USA, LLC | $82.90 | 2022 | |
| Biocryst US Sales Co., LLC | $74.19 | 2025 | Orladeyo |
| Akcea Therapeutics, INC. | $71.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $68.79 | 2020-2022 | |
| Pfizer INC. | $60.92 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.47 | 2019-2022 | |
| Genentech USA, INC. | $47.88 | 2019-2022 | |
| Mylan Specialty L.P. | $46.35 | 2020-2021 | |
| Abbvie INC. | $39.30 | 2022 | |
| Alk-Abello, INC | $28.07 | 2022 | |
| Incyte Corporation | $19.43 | 2022 | |
| Circassia INC. | $19.22 | 2020 | |
| Leo Pharma INC. | $12.55 | 2022 | |
| Csl Behring | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masood Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.